Pages that link to "Q73084706"

The following pages link to Effects of a hexameric deoxyriboguanosine run conjugation into CpG oligodeoxynucleotides on their immunostimulatory potentials (Q73084706):

Displaying 25 items.

• Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo (Q24682799) (← links)
• Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system (Q27004381) (← links)
• A hexanucleotide selected for increased cellular uptake in cis contains a highly active CpG-motif in human B cells and primary peripheral blood mononuclear cells (Q33265100) (← links)
• Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human Toll-like receptor 9 agonists. (Q34029664) (← links)
• Differential signaling by CpG DNA in DCs and B cells: not just TLR9 (Q35557262) (← links)
• A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. (Q35990737) (← links)
• Development of Nonaggregating Poly-A Tailed Immunostimulatory A/D Type CpG Oligodeoxynucleotides Applicable for Clinical Use. (Q36035012) (← links)
• Novel chimeric immunomodulatory compounds containing short CpG oligodeoxyribonucleotides have differential activities in human cells (Q36247625) (← links)
• Herpes Simplex Virus Type 1 DNA Is Immunostimulatory In Vitro and In Vivo (Q36474285) (← links)
• Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. (Q37050067) (← links)
• Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer (Q37277677) (← links)
• The effect of CpG-oligodeoxynucleotides with different backbone structures and 3' hexameric deoxyriboguanosine run conjugation on the treatment of asthma in mice (Q37364531) (← links)
• Activation of nonspecific cytotoxic cells (NCC) with synthetic oligodeoxynucleotides and bacterial genomic DNA: binding, specificity and identification of unique immunostimulatory motifs (Q38293583) (← links)
• Identification of a scavenger receptor homologue on nonspecific cytotoxic cells and evidence for binding to oligodeoxyguanosine (Q38351990) (← links)
• Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity (Q40062305) (← links)
• Immunostimulatory DNA as adjuvant: efficacy of phosphodiester CpG oligonucleotides is enhanced by 3' sequence modifications (Q40675102) (← links)
• The intratumoral application of poly-G-oligodeoxynucleotides does not augment the naturally induced antitumoral CD8-T-cell response in P815 mastocytomas (Q44567651) (← links)
• Structure-efficacy relationships of immunostimulatory activity of CpG-containing oligodeoxynucleotides on mouse spleen cells (Q46990192) (← links)
• CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model (Q47736286) (← links)
• The arthritogenic and immunostimulatory properties of phosphorothioate oligodeoxynucleotides rely on synergy between the activities of the nuclease-resistant backbone and CpG motifs. (Q47796604) (← links)
• Development of short non-CpG phosphodiester oligonucleotides as immune stimulatory agents. (Q52842475) (← links)
• Characteristics of oligodeoxyribonucleotides that induce interferon (IFN)-α in the pig and the phenotype of the IFN-α producing cells (Q58895994) (← links)
• A Protective Allergy Vaccine Based on CpG- and Protamine-Containing PLGA Microparticles (Q59342624) (← links)
• Immunostimulatory CpG oligonucleotides form defined three-dimensional structures: results from an NMR study (Q79967720) (← links)
• Immunostimulatory DNA activates production of type I interferons and interleukin-6 in equine peripheral blood mononuclear cells in vitro (Q81849214) (← links)